Publications by authors named "Mike Fiorino"

Article Synopsis
  • * Researchers screened around 580,000 compounds and found that anthelmintics like niclosamide and nitazoxanide effectively block TMEM16A, showing better efficacy than traditional β-agonists in harsh conditions, fully bronchodilating airways.
  • * This study highlights the potential of repurposing TMEM16A antagonists such as niclosamide and nitazoxanide for treating severe asthma and COPD, as well as possibly expanding their use in cancer and infectious
View Article and Find Full Text PDF

Interleukin-23 (IL-23) and IL-17 are cytokines currently being targeted in clinical trials. Although inhibition of both of these cytokines is effective for treating psoriasis, IL-12 and IL-23 p40 inhibition attenuates Crohn's disease, whereas IL-17A or IL-17 receptor A (IL-17RA) inhibition exacerbates Crohn's disease. This dichotomy between IL-23 and IL-17 was effectively modeled in the multidrug resistance-1a-ablated (Abcb1a(-/-)) mouse model of colitis.

View Article and Find Full Text PDF

Surrogate readouts of G-protein-coupled receptor signaling pathways using highly engineered systems are often employed in the drug discovery process. However, accumulating data have demonstrated the importance of selecting relevant biological activity rather than technically facile assays to support high-throughout screening and subsequent structure-activity relationship studies. Here we report a case study using sphingosine-1-phosphate receptor 1 (S1P(1)) as the model system to compare compound activity in six different in vitro assays with their ability to predict in vivo efficacy.

View Article and Find Full Text PDF
Article Synopsis
  • The research involved modifying an S1P(1) agonist called AMG 369 to create a new compound that specifically targets S1P(1) while sparing S1P(3) receptors.
  • The newly developed compound, named 8c, demonstrated strong effectiveness in reducing blood lymphocyte counts in female Lewis rats when administered orally.
  • The results indicate that 8c has favorable pharmacokinetic properties, making it a promising candidate for further studies in drug development.
View Article and Find Full Text PDF

An SAR campaign designed to increase polarity in the 'tail' region of benzothiazole 1 resulted in two series of structurally novel 5-and 6-substituted S1P(1) agonists. Structural optimization for potency ultimately delivered carboxamide (+)-11f, which in addition to possessing improved physicochemical properties relative to starting benzothiazole 1, also displayed good S1P(3) selectivity and acceptable in vivo lymphocyte-depleting activity.

View Article and Find Full Text PDF

The optimization of a series of thiazolopyridine S1P1 agonists with limited activity at the S1P3 receptor is reported. These efforts resulted in the discovery of 1-(3-fluoro-4-(5-(1-phenylcyclopropyl)thiazolo-[5,4-b]pyridin-2-yl)benzyl)azetidine-3-carboxylic acid (5d, AMG 369), a potent dual S1P1/S1P5 agonist with limited activity at S1P3 and no activity at S1P2/S1P4. Dosed orally at 0.

View Article and Find Full Text PDF

Optimization of a benzofuranyl S1P1 agonist lead compound (3) led to the discovery of 1-(3-fluoro-4-(5-(2-fluorobenzyl)benzo[d]thiazol-2-yl)benzyl)azetidine-3-carboxylic acid (14), a potent S1P1 agonist with minimal activity at S1P3. Dosed orally at 0.3 mg/kg, 14 significantly reduced blood lymphocyte counts 24 h postdose and attenuated a delayed type hypersensitivity (DTH) response to antigen challenge.

View Article and Find Full Text PDF